Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.36 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.34 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | OSBP | P22059 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 2/20 | 0.33 |
| ▸ | UGCG | Q16739 | 2/20 | 0.33 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.33 |
| ▸ | NPC1L1 | Q9UHC9 | 4/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13610648 | 1.00 | POLA1 (0.36) | POLA1CYP46A1APPPLA2G2AEPHA2 | |
| SCHEMBL13032470 | 0.87 | POLA1 (0.39) | POLA1CYP46A1APPPLA2G2AEPHA2 | |
| SCHEMBL13610651 | 0.87 | POLA1 (0.39) | POLA1CYP46A1APPPLA2G2AEPHA2 | |
| SCHEMBL12259016 | 0.84 | POLA1 (0.39) | POLA1CYP46A1APPPLA2G2AEPHA2 | |
| SCHEMBL12259017 | 0.84 | EPHA2 (0.37) | EPHA2LMNA | |
| SCHEMBL14473410 | 0.81 | CYP46A1 (0.44) | POLA1CYP46A1APPPLA2G2AEPHA2 | |
| SCHEMBL24353060 | 0.81 | CYP46A1 (0.42) | POLA1CYP46A1APPPLA2G2AEPHA2 | |
| SCHEMBL14817435 | 0.81 | CYP46A1 (0.42) | POLA1CYP46A1APPPLA2G2AEPHA2 | |
| SCHEMBL24780015 | 0.81 | CYP46A1 (0.42) | POLA1CYP46A1APPPLA2G2AEPHA2 | |
| SCHEMBL14473285 | 0.80 | CYP46A1 (0.42) | POLA1CYP46A1APPPLA2G2AEPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507661-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8017763-B2 | Chemically modified oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100292455-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100267810-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | UNIVERSITY OF MASSACHUSETTS (US) | 2010-10-21 | — | — | US | disclosed |
| US-7745608-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100069471-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069471-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | NSUN2, RNGTT, DCLRE1B | POLA1 224/4885CYP46A1 3991/4885APP 4692/4885 |
| US-20100292455-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | POLA1 216/4885CYP46A1 1117/4885APP 3803/4885 |
| US-20100267810-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | SMN1; SMN2, CLN6, INA | POLA1 734/4885CYP46A1 3384/4885APP 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.